Among the group’s current objectives is putting into practice tumour sequencing in patients with breast cancer. We are studying the efficacy of PI3K/mTOR inhibitors and their relationship with mutational state, as well as continuing research on the factors involved in resistance to HER2 treatments and the strategies aimed at reversing them.

We are also studying how effective PARP inhibitors are in breast cancer and investigating the implementation of therapeutic strategies and differentiated clinical trials for tumour subtypes.

Visit the research group’s page


Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.